3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Sezary Syndrome
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Interventions
fludarabine phosphate
19
Cyclophosphamide
18
Tacrolimus
17
Peripheral Blood Stem Cell Transplantation
17
Mycophenolic Acid
17
Antilymphocyte Serum
14
Busulfan
13
Whole-Body Irradiation
12
Methotrexate
11
Cyclosporine
11
Melphalan
7
mogamulizumab
6
Methylprednisolone
6
Etoposide
6
Bexarotene
6
Sirolimus
5
Radiotherapy
5
Flow Cytometry
5
Filgrastim
5
sargramostim
4
pembrolizumab
4
Vorinostat
4
Transplantation
4
Therapeutics
4
Rituximab
4
Lenalidomide
4
Brentuximab Vedotin
4
Alemtuzumab
4
thymoglobulin
3
romidepsin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, T-Cell, Cutaneous
×
resminostat
×
Clear all
NCT02953301
2024-08-30
RESMAIN
4SC AG
Phase 2
Completed
201 enrolled